Alaunos Therapeutics Inc (TCRT)

[Rule_62]

Keith Markey of Griffin Securities on XON, ZIOP & FCSC

"I like both Fibrocell and Intrexon, which has a business-to-business (B2B) model. The collaboration has created a cell therapy for both children and older people with RDEB, a blistering condition that starts at the time of birth and ultimately takes a person's life prematurely, usually when in his or her 20s. The gene therapy involves inserting the correct gene for collagen VII, which is the material that knits the epidermis (outer layer of the skin) to the dermis (the inner layer of the skin). The hope is that by inserting this gene into the fibroblasts that are part of the dermal layer, there will be an expression of sufficient collagen VII to hold the outer layer in place and prevent the blistering. Even for short periods of time, that would be very helpful to the patient."

full article:
Five Stocks Griffin Securities' Keith Markey Thinks Could Double or Triple